



### Benicar<sup>®</sup> (olmesartan), Benicar HCT<sup>®</sup> (olmesartan/hydrochlorothiazide) – First-Time Generics

- On October 26, 2016, [Mylan](#) and Sun Pharmaceuticals launched generic versions of Daiichi Sankyo's [Benicar \(olmesartan\)](#) 5 mg, 20 mg and 40 mg tablets and [Benicar HCT \(olmesartan/hydrochlorothiazide\)](#) 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg tablets.
  - Mylan was granted 180 days of exclusivity.
  - Sun Pharmaceuticals also launched authorized generics of Benicar and Benicar HCT.
- Benicar and Benicar HCT are indicated for the treatment of hypertension, to lower blood pressure. Benicar HCT is not indicated for the initial therapy of hypertension.
- Benicar had U.S. sales of approximately \$1 billion for the 12 months ending August 31, 2016, according to IMS Health. Benicar HCT had U.S. sales of approximately \$805 million during that same time.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.